Predictive biomarkers for response to therapy in advanced colorectal/rectal adenocarcinoma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Over the past couple of decades, with discovery of novel targeted therapies, and expansion of our understanding of the molecular biology of rectal cancer, there has been an emergence of a wide variety of therapeutic options designed to facilitate a personalized approach for the treatment of this malignancy A plethora of new prognostic and predictive single genes and proteins are being discovered that may reflect susceptibility and/or resistance to therapy Pathologic complete response rates occur in 10-16% of patients and have been shown to correlate with both disease-free and overall survival However, the response to neoadjuvant therapy remains variable and unpredictable In this review, some of these novel markers are discussed for their potential use as pharmacogenetic predictors for specific therapy, drug toxicity, and disease outcome

Original languageEnglish (US)
Pages (from-to)361-367
Number of pages7
JournalCritical Reviews in Oncogenesis
Volume17
Issue number4
DOIs
StatePublished - 2012

Fingerprint

Adenocarcinoma
Biomarkers
Therapeutics
Neoadjuvant Therapy
Pharmacogenetics
Rectal Neoplasms
Drug-Related Side Effects and Adverse Reactions
Disease-Free Survival
Molecular Biology
Neoplasms
Proteins

Keywords

  • Biomarker
  • Predictive
  • Prognostic
  • Rectal adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Predictive biomarkers for response to therapy in advanced colorectal/rectal adenocarcinoma. / Kapur, Payal.

In: Critical Reviews in Oncogenesis, Vol. 17, No. 4, 2012, p. 361-367.

Research output: Contribution to journalArticle

@article{3dff3301023c4ce7b55bb79741c0397d,
title = "Predictive biomarkers for response to therapy in advanced colorectal/rectal adenocarcinoma",
abstract = "Over the past couple of decades, with discovery of novel targeted therapies, and expansion of our understanding of the molecular biology of rectal cancer, there has been an emergence of a wide variety of therapeutic options designed to facilitate a personalized approach for the treatment of this malignancy A plethora of new prognostic and predictive single genes and proteins are being discovered that may reflect susceptibility and/or resistance to therapy Pathologic complete response rates occur in 10-16{\%} of patients and have been shown to correlate with both disease-free and overall survival However, the response to neoadjuvant therapy remains variable and unpredictable In this review, some of these novel markers are discussed for their potential use as pharmacogenetic predictors for specific therapy, drug toxicity, and disease outcome",
keywords = "Biomarker, Predictive, Prognostic, Rectal adenocarcinoma",
author = "Payal Kapur",
year = "2012",
doi = "10.1615/CritRevOncog.v17.i4.50",
language = "English (US)",
volume = "17",
pages = "361--367",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "4",

}

TY - JOUR

T1 - Predictive biomarkers for response to therapy in advanced colorectal/rectal adenocarcinoma

AU - Kapur, Payal

PY - 2012

Y1 - 2012

N2 - Over the past couple of decades, with discovery of novel targeted therapies, and expansion of our understanding of the molecular biology of rectal cancer, there has been an emergence of a wide variety of therapeutic options designed to facilitate a personalized approach for the treatment of this malignancy A plethora of new prognostic and predictive single genes and proteins are being discovered that may reflect susceptibility and/or resistance to therapy Pathologic complete response rates occur in 10-16% of patients and have been shown to correlate with both disease-free and overall survival However, the response to neoadjuvant therapy remains variable and unpredictable In this review, some of these novel markers are discussed for their potential use as pharmacogenetic predictors for specific therapy, drug toxicity, and disease outcome

AB - Over the past couple of decades, with discovery of novel targeted therapies, and expansion of our understanding of the molecular biology of rectal cancer, there has been an emergence of a wide variety of therapeutic options designed to facilitate a personalized approach for the treatment of this malignancy A plethora of new prognostic and predictive single genes and proteins are being discovered that may reflect susceptibility and/or resistance to therapy Pathologic complete response rates occur in 10-16% of patients and have been shown to correlate with both disease-free and overall survival However, the response to neoadjuvant therapy remains variable and unpredictable In this review, some of these novel markers are discussed for their potential use as pharmacogenetic predictors for specific therapy, drug toxicity, and disease outcome

KW - Biomarker

KW - Predictive

KW - Prognostic

KW - Rectal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84870342500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870342500&partnerID=8YFLogxK

U2 - 10.1615/CritRevOncog.v17.i4.50

DO - 10.1615/CritRevOncog.v17.i4.50

M3 - Article

C2 - 23176043

AN - SCOPUS:84870342500

VL - 17

SP - 361

EP - 367

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 4

ER -